T follicular helper (T FH)
INTRODUCTION
The development of class-switched, affinity-matured antibody production by B cells is dependent on help from T follicular helper cells (T FH ) in the germinal center (GC) (1) . A circulating subset of CD4 T cells, termed circulating T FH (cT FH ), express CXCR5 and programmed death-1 (PD-1) and share phenotypic, functional, and transcriptional properties with lymphoid T FH (2) (3) (4) . Vaccine-induced changes in cT FH have been linked to changes in the influenza-specific antibody production. For example, increased expression of inducible costimulator (ICOS; CD278) by cT FH correlated with vaccine-induced antibodies after influenza vaccination (5, 6). Because of the central role of T FH in antibody development, rational vaccine strategies will benefit from a better understanding of the properties of cT FH during an immune response.
Despite elegant work on the biology of T FH in animal models and humans, our understanding of how antigen-specific T FH are induced and maintained in humans is incomplete. Antigen-specific T FH are generated after an immune stimulus in mice (7) and memory T FH have been identified (8, 9) . In humans, tetanus-specific cT FH have been identified at baseline in healthy adults (3), and antigen-specific T FH can be detected after challenge with influenza vaccine (6) and HIV vaccine (10). In humans, protective antibody responses after influenza vaccination target hemagglutinin (HA) (11) . However, although HA-specific CD4 T cell responses to vaccination are observed (12) , more CD4 T cells respond to the internally conserved influenza proteins than to HA (13, 14) . This biased specificity may not be true for T FH , because T FH may preferentially respond to HA rather than nucleoprotein (NP) (15) , but the dynamics of antigen-specific T FH responses in humans after vaccination remain poorly understood.
Unfortunately, typical methods to study antigen specificity of CD4 T cells have drawbacks when applied to T FH . Major histocompatibility complex class II tetramer studies require reagents fitting a cohort of human leukocyte antigen (HLA)-matched participants and profile only a fraction of the overall response. Strategies to sort cells based on cytokine production after peptide stimulation have limitations for these analyses, because intrinsic affinity of a T cell receptor (TCR) for its cognate antigen or incomplete cytokine production by the population of interest only reveals a subpopulation of the cells of interest (16) . Proliferation as a marker of antigen specificity (17, 18) may also lead to a suboptimal picture because T FH proliferate less than T helper cell 1 (T H 1)-type CD4 T cells (19) . Next-generation methods such as T cell receptor sequencing (TCRseq) (17, 20, 21) permit broad, detailed analysis of the TCR repertoire, but TCRseq has not previously been used to probe T FH repertoire dynamics.
In this study, we identified a subset of cT FH coexpressing ICOS and CD38 that expressed B cell lymphoma 6 (Bcl6), increased in frequency and clonality after influenza vaccination, and contained influenzaspecific cells. Repeated vaccination of the same participants recalled highly overlapping clones in successive years, indicating robust cT FH memory to influenza vaccination. Some clones identified in the expanded ICOS + CD38
+ cT FH subset on day 7 were later found in the ICOS − CD38 − cT FH population, suggesting that ICOS − CD38 − cT FH form a pool of memory cT FH that can be repeatedly recalled upon subsequent exposures to antigen. These data have implications for repeated influenza vaccination. These results also provide a tractable way to monitor antigen-induced cT FH responses and to identify a pool of memory cT FH that can be repeatedly recalled upon subsequent antigen exposure, providing a platform with which to further interrogate and optimize rational vaccine strategies.
RESULTS

Highly activated phenotype of ICOS +
CD38
+ cT FH at baseline We first reasoned that recently activated T FH in the circulation might be identified by the expression of proteins associated with cellular activation. We focused on cT FH , defined as non-naive CD4 + CXCR5 + PD-1 + , that expressed high levels of the costimulatory marker ICOS, which is expressed by lymphoid T FH (1) ; contributed to in vitro B cell help (3); and were induced in cT FH after influenza vaccination (5, 6). Of circulating cT FH at baseline for participants in cohort 1 (table S1; n = 28), ~5% expressed ICOS and also CD38 (hereafter referred to as ICOS 
+ cT FH were a small fraction of all cT FH but expressed many proteins associated with T cell activation.
Activated cT FH express Bcl6 and can produce interleukin-10, interleukin-17, and interleukin-21
Bcl6 has a central role in the T FH program (1), but protein expression was not detected in total peripheral blood cT FH in previous studies (2, 3, 5 Fig. 2A and fig. S2 
CD38
+ cT FH with the highest PD-1 expression (Fig. 2B ). Previous studies have suggested that T H 1-, T H 2-, and T H 17-polarized subsets exist within the cT FH pool (2) , but other studies have found low expression of master transcriptional regulators such as Tbet or RORT in T FH (22, 23) . To address whether cT FH expressed these regulators, we profiled protein expression of these transcription factors in cT FH . Most of the activated cT FH lacked detectable expression of any of these lineage-associated transcription factors (Fig. 2C and fig. S2E ). Of these, Tbet was most commonly expressed in ICOS + CD38 + cT FH . T follicular regulatory cells (T FR ) were identified by expression of Foxp3  and CD25 and represented about 5% of the ICOS   +   CD38 + cT FH , consistent with the frequency of circulating T FR from mouse studies (24) .
The transcription factor c-Maf has a critical role in T FH biology (25) (26) (27) and displayed high expression in ICOS + CD38
+ cT FH , as did total Foxo1. GATA3 is critical for development, maintenance, and function of lymphocytes (28) (Fig. 2D and fig. S2F) + cT FH produced a unique combination of IL-10, IL-17, and IL-21 compared with other CD4 subsets (Fig. 2E and fig. S2 , G to I), a pattern also observed after staphylococcal enterotoxin B stimulation ( fig. S2J) 
+ cT FH expressed none of the assayed cytokines, about one-third expressed tumor necrosis factor (TNF) alone, and the remainder coexpressed multiple cytokines, primarily IL-10 and interferon- (IFN-) (Fig. 2F and fig. S2H (table S1) received inactivated influenza vaccine during the fall of 2014 (n = 28).
In an influenza challenge study, a subset of CD4 coexpressing CD38 and Ki67 was observed 1 week after infection (13) . In our cohort, 7 days after vaccination, we observed increased CD38 expression among non-naive Ki67 + CD4 T cells (Fig. 3A and fig. S3A ). Before vaccination, cT FH represented ~25% of the Ki67 + CD38 + CD4 T cells. After vaccination, the proportion of cT FH in this Ki67 + CD38 + CD4 T cell compartment increased between 4 and 60% (Fig. 3, A (Fig. 3C and fig. S3B ). Expression of PD-1 also increased in the ICOS + CD38
+ cT FH after vaccination ( fig. S3C ), but no changes were detected with respect to expression of CD27, CD28, CD127, CTLA4, Helios, or Ki67 ( fig. S3D ). Thus, influenza vaccination was associated with increased frequency of the ICOS + CD38
+ cT FH population. We next hypothesized that the day 7 ICOS + CD38
+ cT FH population would be enriched for influenza-specific cells. Previous studies have identified CD4 T cells specific for NP, matrix 1 (M), and HA peptides after vaccination (13, 14, 31) . However, these methods typically rely on cytokine production after stimulation. We previously observed production of TNF, IFN-, or IL-2 by only a minority of
CD4 after stimulation with overlapping peptide pools for influenza proteins (31) , and IL-21 was produced by a subset of cT FH after PMA/ionomycin stimulation (Fig. 2E) . Here, an independent approach using class II tetramers was used (32) . A second cohort of participants was recruited (cohort 2, n = 12; , paired t test; n = 26), CD27 (P = 3.1 × 10 −9
, paired t test; n = 27), CD28 (P < 10 −16 , paired t test; n = 28), CD127 (P < 10 −16 , paired t test; n = 26), CTLA4 (P = 1.5 × 10 −15 , paired t test; n = 26), PD-1 (P < 10 −16 , paired t test; n = 26), Helios (P = 1.7 × 10 −13 , paired t test; n = 26), and Ki67 (P = 6.0 × 10 −13 , paired t test; n = 26). + cT FH population after vaccination, a tetramer-based approach is likely to underestimate the total influenza vaccine-induced population because few epitopes were interrogated. Expression of activation-induced markers (AIMs) has been used to identify antigen-specific CD4 T cells after antigen stimulation (34, 35) . This approach has the advantage of not being restricted to a single epitope specificity and offers a broader view of antigen-specific cT FH populations. Thus, to complement the tetramer approach, PBMCs before and after vaccination were stimulated with overlapping influenza − cT FH , P = not significant; CXCR5 − memory, P = not significant; paired t test; n = 5). For all panels, *P < 0.05 and **P < 0.01. + cT FH population increased after influenza vaccination (Fig. 4, A + cT FH population and clonality, when examining both day 7 alone and the fold change at day 7 versus day 0 (Fig. 4C and fig. S4 , D and E). We did not detect a clear relationship with the hemagglutination inhibition antibody titer and ICOS + CD38
Day 7 after vaccination
+ cT FH clonality ( fig. S4, F and G) , perhaps reflecting the fact that hemagglutination inhibition antibody is only a small fraction of the total antibody induced by vaccination. However, the change in clonality of ICOS + CD38
+ cT FH demonstrated a trend toward correlation with the change in frequency of circulating plasmablasts when assessed in a subset of participants (Fig. 4D) , suggesting a relationship between this cT FH subpopulation and the humoral immune response. These data demonstrate a rapid, oligoclonal ICOS + CD38
+ cT FH response to vaccination that strongly correlated with the magnitude of the response. Influenza vaccination resulted in antigen-specific clonal expansion of cT FH populations in the PBMCs.
Repeated influenza vaccinations elicit a recurring oligoclonal response
Nearly all humans become seropositive for influenza virus-specific antibodies by the end of childhood (36) . Thus, we assumed that, before entry into the study, all adult participants had either been immunized against or been infected with influenza A virus at least once in the past. However, it was unknown whether a recall response with successive vaccinations would elicit the same oligoclonal response, given the passage of time, the annual reformulation of the influenza vaccine, and the possibility of influenza infection before revaccination. + cT FH was observed at day 7 after each successive vaccination (Fig. 5A and fig. S5A ).
We first investigated the stability of the cT FH repertoire over time, independent of vaccination. The overlap score (Materials and Methods) provides an estimate of similarity in repertoire of a population of T cells across different time points. To assess this, we compared the similarity of the T cell receptor  chain (TCRB) repertoire of each subset with itself 1 year after vaccination (i.e., just before revaccination). The ICOS + CD38 + cT FH subset had a low overlap score over 1 year in the same individual, suggesting high turnover of this subset of cT FH in the absence of vaccination (Fig. 5B) − subset of cT FH in the steady state. We next considered the effect of vaccination on the TCRB repertoire of these CD4 T cell populations. There was essentially no overlap when comparing the ICOS + CD38
+ repertoire at year 1 day 7 after vaccination with year 2 day 0, indicating that, within the limit of detection of these assays, the clones present in the ICOS + CD38
+ cT FH subset after influenza vaccination were no longer detectable in this subset a year later (Fig. 5C) 
CD38
− cT FH nor the CXCR5 − memory CD4 subsets showed such a response (Fig. 5D and fig. S5B ). The timing of the vaccination in the previous years did not have any apparent effect on the recall responses in ICOS + CD38
+ cT FH ( fig. S5B ). The median number of clonotypes in the recurrent oligoclonal response for all participants was 66 but varied widely from participant to participant and did not appear dependent on the number of years of observation (Fig. 5E ). These data strongly suggested a recurrent oligoclonal response in the ICOS + CD38
+ cT FH subset to repeated influenza vaccination in all participants.
To investigate these clonality relationships in more detail, we focused on the two participants for whom 3 years of data were available. There was a robust increase in overlapping clonotypes between year 1 day 7 and subsequent day 7 time points, but we observed only a weak overlap with subsequent day 0 time points in the ICOS + CD38
+ cT FH subset (Fig. 5F and fig. S5 , B and C). Moreover, clones shared at every day 7 time point in ICOS + CD38
+ cT FH were absent at every day 0 time point, whereas clones shared at every day 7 time point in ICOS − CD38
− cT FH or CXCR5 − memory were sometimes present at day 0 time points in these subsets as well (Fig. 5G and fig. S5D + cT FH sub set at the day 7 time point each year for both tetramers for one of the two participants examined (Fig. 6A and fig. S6B ). Even when only a single HA 398-410 clonotype in participant 999 was identified within the recurring ICOS + CD38
+ cT FH oligoclonal response, this finding was highly unlikely by chance alone (P = 2 × 10 −4 , Fisher's exact test; HA clonotypes, n = 1; recurring oligoclonal response, n = 131). The tetra mer clonotypes together comprised 0.37 to 0.70% of the ICOS + CD38
+ cT FH population at day 7 after vaccination each year for participant 999 (Fig. 6B) . The inability to detect shared clones between tetramer + CD4 T cells and the ICOS + CD38
+ cT FH subset in participant 108 ( fig. S6C ) was likely due to the low number of tetra mer events that could be captured 6 months after vaccination in this participant, suggesting either involvement of other specificities in the cT FH response or that capturing only 10 to 30 TCRB sequences for a single epitope specificity may be at the limit of detection for this type of analysis.
To further explore these questions and test whether the ICOS + CD38 + cT FH population contained influenza-specific cells in a manner that did not depend on HLA class II tetramers, we next used the AIM approach described above. As above, PBMCs were stimulated with pools of influenza peptides, and CD69 + CD200 + ICOS + CD38 + cT FH were sort-purified on day 7 after influenza vaccination. Using this approach, we identified 33 to 216 clonotypes by TCRseq, depending on the participant (fig. S6D ). Many TCRB sequences were identified in the influenza-specific AIM approach that were shared with TCR sequences identified in the total ICOS + CD38
+ cT FH subset at day 7 after vaccination of each year (Fig. 6C and fig. S6E ). Again, similar to the recurring oligoclonal response, the AIM clonotypes showed similar pattern of increased frequency in the ICOS + CD38
+ cT FH subset at each day 7 time point in three of the six participants (Fig. 6D) . The overlap between the recurrent oligoclonal response and the AIM clonotypes was statistically significant in four of six participants (Fig. 6E  and fig. S6F ). AIM clones and recurring oligoclonal response clones were not prominently found in other subsets, suggesting strong enrichment for influenza-specific clones in the cT FH compartment ( fig. S6, G and H) , though because the non-cT FH compartments are substantially larger, undersampling cannot be excluded. Nevertheless, these data confirm the presence of influenza-specific clonotypes within the ICOS + CD38
+ cT FH subset 1 week after each influenza vaccination, as well as within the yearly recurring oligoclonal response.
ICOS − CD38 − cT FH may serve as a long-term reservoir of cT FH memory
The TCRB sequence has been used as a "fingerprint" to track clones through different compartments in other studies (37-39), although a particular clone could sometimes be found in multiple distinct CD4 subsets (40) . Here, to track clones across subsets over time, clones present for each subset at year 1 day 7 were compared against all the other subsets at year 2 (Fig. 7, A to C, and fig. S7A ). A cumulative frequency was obtained by adding together all the frequencies for the year 1 day 7 clonotypes in the year 2 day 0 time point. As expected, clones that were originally present in the CXCR5 − memory or ICOS − CD38 − cT FH subsets in year 1 day 7 could be found in the CXCR5 − memory (Fig. 7A) − cT FH at 1 year in Fig. 5B .
Given − cT FH subset at year 2 day 0 (Fig. 7C) . Similarly, ICOS + CD38
+ cT FH clones present at year 2 day 7 were most frequently found in ICOS − CD38
− cT FH at year 3 day 0 (Fig. 7D and fig. S7B ). As noted earlier, influenza vaccination 
DISCUSSION
Induction of a strong antibody response is a major correlate of protection in nearly all licensed vaccines. Despite the importance for vaccines, our understanding of the T FH response underlying vaccine-induced antibody responses remains incomplete. In this study, we f ound that cT FH coexpressing ICOS and CD38 increased in frequency and clonality after infl uenza vaccination. This subset of cT FH expressed markers of activation and contained influenza virus-specific tetramer + cells at day 7 after vaccination. These data not only identify a proxy for antigenspecific cT FH , allowing monitoring of human vaccine-induced responses, but also provide insights into the dynamics of cT FH memory and recall responses.
Although cT FH are thought to be derived from lymphoid tissue, differences have been reported between lymphoid T FH and cT FH in protein expression, including lack of transcription factor Bcl6 expression, leading to uncertainty regarding the ontogeny of this cT FH population (2, 3, (41) (42) (43) + cT FH . The clonal composition of this response was repeated with each vaccination, despite the annual vaccine reformulation and possible intercurrent influenza infection. Recall of the same clonotypes could reflect the greater immunodominance of relatively conserved internal influenza proteins in CD4 responses (13, 14) or original antigenic sin (44, 45) . Moreover, the stability of the recall response repertoire suggests longevity in the influenza-specific CD4 T cell repertoire. It will be interesting to compare the dynamics, quality, and repertoire diversity of this ICOS + CD38
+ subset of antigeninduced cT FH + cT FH total in circulation. In these studies, we sampled from 40 to 100 ml of blood (or 0.8 to 2.0% of the total) and only recovered productive TCRB sequences from 10 to 20% of the cells analyzed (i.e., sampling only 0.08 to 0.4% of total ICOS + CD38
+ cT FH ). The likelihood of identifying the same random 50 to 70 clones at two time points with this sampling approach among the 3 million ICOS + CD38
+ cT FH is extraordinarily low. Although we cannot sample and interrogate rare clonotypes by these approaches, these data provide strong evidence for the repeated recruitment of common clonotypes into the antigen-specific cT FH response induced by influenza vaccination. Moreover, on the basis of the AIM analysis, we can account for up to 20% of the vaccine-induced ICOS + CD38
+ cT FH as antigenspecific [e.g., 11% of ICOS + CD38
+ induce CD200 and CD69 (Fig. 3E ), and about one-half of the ICOS + CD38
+ cT FH population is induced by vaccination (Fig. 3C) ]. These data are consistent with the clono- + cT FH population after vaccination) as using TCRB sequences repeatedly recalled by influenza vaccination. Perhaps the remainder of this vaccine-induced ICOS + CD38
+ cT FH population is nonspecific bystander cT FH activation. Alternatively, these cells could represent heterogeneous rare clonotypes and/or specificities not efficiently assayed in the AIM approach. Future studies should be able to address these questions with deeper TCRB analysis and analysis of additional specificities. Nevertheless, these distinct approaches yield data that not only are internally consistent and demonstrate a robust influenza virus-specific cT FH response but also provide approaches to allow future interrogation of antigen-induced cT FH responses and T FH memory in humans. The relationship of these cT FH to lymphoid T FH in terms of function, clonality, and dynamics remains to be evaluated. However, one interesting possibility is that the cT FH memory populations identified here using repeated yearly vaccination may be a source of systemic memory, allowing new GC reactions to be seeded in any lymphoid tissue depending on where the antigen is encountered.
Future rational vaccine strategies may require eliciting precise T cell responses to provide help for the desired types and specificities of the antibody response. Identification of the specific TCR repertoire expanded by immunization reveals a broader picture of the cT FH response than typically accessible by HLA class II tetramers or cytokine production after antigen stimulation. The identification of cT FH memory and the dynamics of this population upon vaccination provide not only a framework for dissecting how these cells are related to lymphoid tissue responses but also key insights for evaluating and comparing future vaccination regimens for their ability to induce the desired magnitude and quality of cT FH memory.
MATERIALS AND METHODS
Human participants
Participants were eligible if they were community-dwelling and had not received influenza vaccine in the previous 6 months; they were excluded if they had contraindications to influenza vaccine, active substance abuse, HIV or AIDS, clinically active malignancy, immunomodulatory medication need (i.e., chemotherapy and corticosteroids), or active illness (i.e., active respiratory tract infections). Seasonal inactivated influenza vaccine (Fluarix, GlaxoSmithKline) was administered, and peripheral venous blood was drawn on days 0, 7, and 28 after vaccination. For cohort 1, study participants were recruited and consented in the fall of 2014 at the Clinical Research Unit at Duke University Medical Center (Durham, NC), in accordance with the institutional review boards of both Duke University and the University of Pennsylvania (Philadelphia, PA). Blood was collected into heparinized tubes and shipped overnight to Philadelphia, PA. For cohort 2, study participants were recruited and consented in between 2013 and 2015 at the University of Pennsylvania. Samples from 2013 to 2014 were cryopreserved, whereas 2015 samples were used immediately after collection. Human spleen samples from relatively healthy adults were obtained as deidentified excess medical tissue via the Cooperative Human Tissues Network, typically after trauma or incidental splenectomy. Splenocytes were obtained by mechanical dissociation and cryopreserved until needed. All human participants research was performed in accordance with the relevant institutional review boards.
Flow cytometry
Fresh PBMCs and plasma were isolated using Ficoll-Paque PLUS (GE Healthcare) or SepMate isolation (STEMCELL Technologies) and stained for surface and intracellular markers. Permeabilization was performed using the Foxp3 Fixation/Permeabilization Concentrate and Diluent kit (eBioscience). Antibodies and clones are described in table S2. Cells were resuspended in 1% paraformaldehyde until acquisition on a BD Biosciences LSR II cytometer and analyzed using FlowJo (Tree Star) and viSNE (Cytobank). Fluorescence-minus-one controls were performed in pilot studies. Gating controls are shown in fig. S1A . The Bcl6 protein expression analysis was performed on a BD LSR II (18-color instrument) cytometer and repeated using a BD Symphony A5 (28-color) cytometer. The advantage of the latter experiment was that the Bcl6 antibody was the only reagent used on the violet laser, greatly reducing fluorescence spillover from other fluorochromes and substantially improving the signal-to-noise ratio for detection of low protein amounts.
HLA class II tetramers
HLA class II tetramers were prepared, as previously described (32) . Staining by tetramers against HA residues 306 to 318 (PKYV-KQNTLKLAT) or HA residues 398 to 410 (SVIEKMNTQFTAV) in two HLA-DRB1*04:01 participants was performed for 1 hour at room temperature, followed by magnetic bead enrichment at 4°C and fixation. Fixed samples were acquired on a BD Biosciences LSR II cytometer. For sorting experiments, tetramer staining was performed in a sim ilar fashion, but samples were maintained unfixed at 4°C until they could be sorted on a BD FACSAria cell sorter.
AIM stimulations
PBMCs were thawed and rested overnight at 37°C in RPMI with 10% fetal calf serum and 1% l-glutamine. were obtained from BEI Resources and resuspended in dimethyl sulfoxide. Stimulation was performed in flat-bottom plates with each peptide pool (0.5 g/ml) for 18 hours, followed by surface staining for 20 min at room temperature. Acquisition and sorting were performed on a BD FACSAria cell sorter.
Hemagglutination inhibition assays
Sera were treated with a receptor-destroying enzyme and then heated for 30 min at 55°C. Sera were serially diluted in 96-well roundbottom plates. Four agglutinating doses of A/California/7/2009 or A/ Switzerland/9715293/2013 were added to the sera in a total volume of 100 l. Turkey red blood cells were added [12. 5 l of a 2% (v/v) solution)], and agglutination was read out 60 min later. Titers are expressed as the inverse sera dilution that inhibited viral agglutination.
Reverse transcription quantitative PCR
PBMCs and splenocytes were thawed and sorted for subsets on a BD FACSAria cell sorter, followed by RNA extraction by a Qiagen Micro Plus kit. Reverse transcription using the High-Capacity Reverse Transcription kit was performed as per the manufacturer's instructions (Applied Biosystems). Real-time PCR was performed using predesigned primers and hydrolysis probes for B2M (Hs.PT.58v.18759587, Integrated DNA Technologies) and BCL6 (Hs.PT.56a.19673829.g, Integrated DNA Technologies) using the PrimeTime Gene Expression Master Mix on a ViiA7 Real-Time PCR system (Applied Biosystems).
TCR sequencing
PBMCs were sorted on a BD FACSAria, followed by DNA extraction by Qiagen QIAamp DNA Micro Kit. Amplification, library preparation, sequencing, and preliminary bioinformatics analysis were performed by Adaptive Biotechnologies. TCRB was sequenced at Survey level resolution.
TCRseq analysis
Calculations were performed in R for Shannon's entropy and normalized Shannon's entropy (46, 47) . Gini index was calculated using the R package "ineq" (48) . Clonality was calculated as follows: 1 − normalized Shannon's entropy. The overlap score was calculated as the sum of the counts for all shared sequences observed in both sample A and sample B, divided by the total number of counts for all sequences in samples A and B (shared and unshared) in the two samples. Some figures were generated with packages "ggplot2" and "gplots" (49, 50) . All R code and primary TCR sequences used for these analyses are available at http:// github.com/Sedmic/cTfh_TCRB_2015-2016FluSpec.
Cytokine production
PBMCs were stimulated for 5 hours in the presence of PMA/ionomycin or left unstimulated as a control. Monensin was added for the final 4 hours of stimulation. Staining was performed at 37°C in the stimulation medium, followed by fixation with 1% paraformaldehyde for 5 min at room temperature. Cells were then permeabilized with the Foxp3 Fixation/Permeabilization Concentrate and Diluent kit, and intracellular staining was performed for 1 hour at room temperature with antibodies against IL-2, IL-10, IL-13, IL-17, IL-21, TNF, and IFN-. Pestle and SPICE (51) were used to analyze polyfunctionality.
Statistics
All analyses were performed as two-tailed tests. Comparisons using Student's t test, paired t test, or one-way analysis of variance (ANOVA) with Tukey's post hoc analysis were performed with Prism 5 (GraphPad) or with R. Repeated-measures one-way ANOVA and repeated-measures two-way ANOVA were performed with Prism 5 (GraphPad). Correlation analyses were performed as the Pearson correlation. Fisher's exact test was used to compare overlap in TCR sequences based on 10 7 theoretical TCRB sequences.
SUPPLEMENTARY MATERIALS
immunology.sciencemag.org/cgi/content/full/2/8/eaag2152/DC1 Fig. S1 . ICOS + CD38
+ cTFH express many markers of activation. Table S1 . Demographic data for clinical cohorts. Table S2 . Fluorochrome reagents and antibody clones used. Data file S1. Raw data for Figs. 1 to 7 and figs. S1 to S7.
